U.S. Stocks Rebound Significantly Higher During Dizzying Week – ( $AAPL $EPRX $GLD $INDP $JPM $LTRB $NVDA $SMMT $TSLA Rise!)

VP Watchlist Updates

Now let’s check out how these nuggets progressed below!

Serina Therapeutics (SER, $4.99) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform^™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com. Serina announced (April 8) the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina’s lead clinical candidate for Advanced Parkinson’s disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025. Serina’s Steve Ledger, Chief Executive Officer, wpresented at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025. On March 25, Serina reported its financial results for the full year ended December 31, 2024 and provided recent business highlights. “We are encouraged by the progress we’ve made this year. Our partnership with Enable Injections’ wearable technology, combined with our POZ optimization technology, is poised to deliver a differentiated product profile and potential best-in-class therapy for advanced Parkinson’s patient care. We are on track towards our goal of dosing the first patient in a Phase 1b clinical trial in the fourth quarter,” said Steve Ledger, CEO of Serina Therapeutics. “We also continue to advance our POZ Platform™ in addressing complex neurological needs and remain committed to pushing the boundaries of the platform’s potential in RNA and ADC therapeutics innovation to improve patient outcomes and quality of life.” On March 24, Serina announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled “A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles,” will highlight findings on the immunogenic profile of Serina’s proprietary POZ-lipid technology. Dr. Moreadith will share data demonstrating that Serina’s POZ-lipid, a key component of lipid nanoparticles (LNPs), did not trigger an IgM or IgG antibody response following repeat dosing in rats. In contrast, polyethylene glycol (PEG)-lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response. Anti-PEG antibodies have been implicated as a potential cause of anaphylaxis and other serious adverse events observed in humans receiving PEGylated mRNA vaccines, such as those from Pfizer and Moderna. The absence of an immune response to Serina’s POZ-lipid represents a novel discovery that could enable the development of safer and more effective LNP formulations for gene therapy and RNA-based medicines. On March 10, Jones Research’s analyst Justin Walsh issued an Initiation of Coverage Report on Serina with a Buy Rating and a $11 price target titled, “Realizing Next-Generation Drug Delivery with POZ – Compelling First Opportunity in Advanced Parkinson’s Disease.”  To obtain the research report please email jwalsh@jonestrading.com. On Feb. 12, Serina announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He currently serves as a Board Director at Elicio Therapeutics. Previously, he was President and Board Director of Alpine Immune Sciences, which he co-founded as a Managing Partner of Alpine BioVentures. Alpine Immune Sciences was acquired by Vertex Pharmaceuticals for $4.9 billion in May 2024. Dr. Venkatesan has a distinguished career spanning investment and operational leadership roles. Before Alpine, he founded and managed Ayer Capital, a global healthcare investment fund. Earlier in his career, he was a director at Brookside Capital, a division of Bain Capital, where he co-managed healthcare investments. He also held roles as a venture investor with Patricof & Co. Ventures (now Apax Partners) and as a consultant at McKinsey & Co. Dr. Venkatesan holds an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from the Wharton School of the University of Pennsylvania. He earned his B.A. from Williams College. Serina (Feb. 3) announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson’s disease patients in the second half of 2025. The closing represented the second tranche of the $10 million total financing announced on December 2, 2024. The financing reinforces Serina’s ability to advance SER-252 into first-in-human studies. At closing, Serina issued 500,000 shares of common stock at $10 per share, representing a 113% premium to the closing price on January 31, 2025. Additionally, Serina issued warrants to JuvVentures for up to 755,728 shares of common stock at an exercise price of $18.00 per share. “This financing strengthens our cash position as we advance SER-252 into the clinic,” said Steve Ledger CEO of Serina Therapeutics. “With a differentiated approach to continuous dopaminergic stimulation and an innovative drug delivery system, we believe SER-252 has the potential to provide meaningful benefits for patients with Advanced Parkinson’s disease. We remain focused on initiating our Phase 1 trial in the second half of this year.” On Jan 15, Serina announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025. The UniverXome subsidiary was established prior to Serina’s reverse merger with AgeX Therapeutics in March 2024 to own the legacy assets of the predecessor company. Steve Ledger, CEO of Serina, commented, “This transaction underscores our commitment to maintaining a focused operational strategy centered on advancing SER-252, our lead candidate for advanced Parkinson’s disease, into clinical development. By achieving a debt-free balance sheet, we have strengthened our financial foundation, enabling us to accelerate our patient-driven mission. Additionally, this allows us to further explore the broad potential of our POZ Platform^™ to address unmet needs across multiple therapeutic modalities, including small molecules, lipid nanoparticles (LNPs), and antibody-drug conjugates (ADCs).”

On Jan. 14, Serina announced the appointment of Karen J. Wilson to the Board of Directors. Ms. Wilson brings over three decades of leadership experiences in the life sciences sector. She currently serves as a board director for Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc. and LAVA Therapeutics N.V. Previously, she held the position of Senior Vice President of Finance at Jazz Pharmaceuticals plc, where she also served as Principal Accounting Officer and Vice President of Finance. Prior to joining the Jazz Pharmaceuticals organization in February 2011, she held senior finance roles at PDL BioPharma, ViroLogic, and Novare Surgical Systems and was a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley. Ms. Wilson stated, “I am excited to join Serina at such a pivotal time in its growth. I look forward to working with the talented executive team and fellow board members to help drive the company’s vision forward and make a meaningful impact in the lives of patients.”

On Dec. 18, Serina’s CEO, Steven A. Ledger presented at Tribe Public’s Webinar Presentation and Q&A Event titled “Enabling Continuous Drug Delivery for Parkinson’s Disease & Beyond.”  

Eupraxia Pharmaceuticals (EPRX, $3.02, up +3.42% over the last 5-days) is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods. Eupraxia announced its financial results for the fourth quarter of 2024 on March 20 where all dollar values are in U.S. dollars unless stated otherwise.

Recent Operational and Financial Highlights

• On October 2, 2024, the Company announced the appointment of Dr. Amanda Malone as the Chief Operating and Scientific Officer of the Company.

• On October 10, 2024, the Company announced a poster presentation at the United European Gastroenterology Week 2024 featuring data from cohorts one through four of Eupraxia’s ongoing RESOLVE trial in EoE.

• On October 15, 2024, the Company announced that Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis was published in leading peer reviewed medical journal The Lancet Rheumatology.

• On October 28, 2024, the Company announced two poster presentations at the American College of Gastroenterology 2024 Annual Scientific Meeting centered on EP-104GI for the treatment of EoE. One poster received a Presidential Award from the conference, which is a distinction for high quality, novel, unique, and interesting research, while the other was designated an “Abstract of Interest”.

• On October 31, 2024, the Company announced the closing of a non-brokered private placement for gross proceeds of C$44.5 million, the appointment of Mr. Joseph Freedman to its Board of Directors, and the termination of its C$12 million convertible debt facility.

• On November 12, 2024, the Company announced positive 12-week data from the fifth cohort of the ongoing RESOLVE trial in patients with eosinophilic esophagitis (“EoE”), noting increasingly positive data on efficacy and safety outcomes as well as emerging evidence of improved patient responses related to higher dosing levels.

• On November 14, 2024, the Company announced a poster presentation at the American College of Rheumatology Convergence 2024 Annual Meeting covering data from Eupraxia’s Phase 2b SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis.

• Subsequent to quarter end, on February 18, 2025, the Company announced the return of seasoned capital markets executive Alex Rothwell to the role of Chief Financial Officer, succeeding the retiring Bruce Cousins.

• Subsequent to quarter end, on February 25, 2025, the Company announced positive 12-week data from the sixth cohort of the ongoing RESOLVE trial in patients with EoE noting no adverse events and continued positive data on efficacy and safety outcomes as well as further evidence of improved patient responses tied to higher dosing levels.

Fourth Quarter 2024 Financial Review

The Company incurred a net loss of $7.5 million for the three months ended December 31, 2024, versus a net loss of $10.6 million for the three months ended December 31, 2023. The decrease in net loss was primarily due to lower research and development costs and reduced other expenses incurred during the period.

The Company had cash of $33.1 million as of December 31, 2024, up from $19.3 million at the end of the fourth quarter of 2023. These funds are being used to fund clinical trials in EP-104 and the remainder of the proceeds will be used for general and administrative expenses, working capital needs and other general corporate purposes.

On Feb. 25, Eupraxia announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. The Company’s ongoing RESOLVE trial is a Phase 1b/2a, multi-center, open-label, dose-escalation study that is evaluating EP-104GI across multiple patient cohorts by assessing key clinical measurements associated with EoE, including SDI, impact on tissue health (histology) as measured by EoEHSS, and the measurement of peak eosinophil count (“PEC”). “In the RESOLVE trial, positive efficacy and safety outcomes continue to be observed,” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We believe the positive dose-response data from these first six cohorts clearly demonstrate that precise, localized delivery of EP-104GI at higher doses is leading to further improvements in both tissue health and symptom reductions. Also, no serious adverse events nor events of oral or gastrointestinal candidiasis, commonly seen in EOE patients being treated with steroids, have been observed in any of the first six Cohorts.” On Feb. 18, Eupraxia announced that it has appointed Alex Rothwell as the Company’s new Chief Financial Officer, effective immediately. Bruce Cousins, the Company’s outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. “Having previously served as Eupraxia’s CFO, and after that as our capital markets consultant, we are delighted to have Alex return and take over from Bruce. I believe his public markets and deal expertise, and his deep familiarity with Eupraxia and its shareholders, will make Alex a key contributor to our senior leadership team as Eupraxia advances its programs in EP-104GI and EP-104AR,” said James Helliwell, Chief Executive Officer of Eupraxia. “On behalf of our board of directors, I’d like to thank Bruce for his leadership and many important contributions to Eupraxia’s success including the Company’s recent Nasdaq listing, and his efforts strengthening our balance sheet, which gives us a solid foundation to build on. Alex Rothwell, new Chief Financial Officer of Eupraxia. stated, “I believe that Eupraxia is in an excellent position to create significant value for shareholders, and I’m very focused on helping drive that process. There is significant unrealized – and unrecognized – potential in the assets, and I have confidence that we can deliver on that potential for patients and shareholders. EP-104GI has an opportunity to be the leading treatment for Eosinophilic Esophagitis, and associated conditions such as strictures. Additionally, we anticipate that EP-104IAR, for the treatment of pain due to osteoarthritis of the knee, can become a key therapy to treat this large patient population, and that its market can be materially expanded by use in other joint areas.” On Nov. 20, Eupraxia unveiled new pharmacokinetic (“PK”) data from its Phase 2a Eosinophilic Esophagitis (“EoE”) program. Management believes these data underscore the unique capabilities of Eupraxia’s proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery. Most conventional drugs release in a pattern characterized by steep peaks and rapid declines in drug concentration, where peaks often lead to negative side effects, and troughs result in reduced efficacy. In contrast, DiffuSphere™ is a unique microsphere that is designed to enable precise drug release into target tissues with a flat, stable, and long-lasting profile, minimizing potential adverse events associated with high-dose systemic delivery. What sets DiffuSphere™ apart is its composition: a pure drug crystal encased in a microns-thick polymer shell. Eupraxia’s proprietary technology uses this polymer to precisely control a drug’s release, ensuring high drug concentrations in the target tissues while minimizing exposure to the rest of the body. This innovative approach has been observed in Eupraxia’s clinical programs, demonstrating precision, tolerability, and extended duration of delivering fluticasone propionate (“FP”) directly to the intended tissues for EoE and knee osteoarthritis (“OA”) patients. On Nov. 15., Eupraxia Pharmaceuticals Inc.’s Chief Executive Officer, James Helliwell. M, delivered a presentation titled “Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed” and was available for a Q&A session at the end of the presentation. The video can be viewed below: On Nov. 12, Eupraxia announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”). EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview Healthcare Partners, EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental health issues, compounding the disease burden of EoE for both the healthcare system and the individual. Eupraxia highlighted the following:

• One of three patients in Cohort 5 achieved complete histological remission at 12 weeks.
• Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks.
• At 24 weeks, the fourth cohort experienced the largest average reduction in SDI scores of all cohorts to date.
• The fifth cohort continued to show improved patient outcomes with the greatest percentage change in histology (EoEHSS2) scores of any cohort to date.
• Both the mean reduction in Peak Eosinophil Counts (PEC3)at four biopsy sites and the percent change in histology (EoEHSS2) scores showed a clear dose response across Cohorts 3 to 5, with Cohort 5 showing the greatest response. No serious adverse events reported in any of the five cohorts to date.
• Cohort 6 is now fully enrolled and dosed, with 12-week data anticipated in Q1 2025.

On Oct. 31 Eupraxia announced that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the “Preferred Shares”), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the “Private Placement”). The Company intends to use the net proceeds from the Private Placement towards the funding of clinical trials for EP104GI, initiating research programs for new candidates and general corporate and working capital purposes of the Company and its affiliates. In connection with the closing of the Private Placement, the Company has appointed Mr. Joseph Freedman to its board of directors. Mr. Freedman is a private equity investor and corporate director with more than 25 years industry experience including, most recently, 18 years at Brookfield Asset Management, one of the world’s leading private equity and alternative asset management firms. Over his career at Brookfield, Mr. Freedman has held a number of positions, including Vice Chair of Private Equity, General Counsel and the Partner responsible for M&A transaction execution, fund formation and fund operations. Prior to joining Brookfield, he was a lawyer in the corporate finance group at a Toronto law firm, specializing in private equity transactions and public company mergers and acquisitions. Now retired from Brookfield, Mr. Freedman is a director of several private and public companies and non-profit organizations including the Centre for Aging and Brain Health Innovation (co-chair), Bridgemarq Real Estate Services (TSX:BRE) and Total Containment Inc. Mr. Freedman holds a joint MBA/LL.B from the Schulich School of Business at York University and Osgoode Hall Law School in Toronto.

Summit Therapeutics Inc. (NASDAQ: SMMT, $23.24, +33.87% over the last 5-days), a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, announced (March 17) that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert LaCaze is a seasoned biopharmaceutical executive with over 35 years of extensive leadership experience in commercial strategy and execution, with a proven track record of driving revenue growth and expanding market presence for various oncology products. He has held senior positions at major pharmaceutical companies like Bayer Healthcare and Bristol-Myers Squibb. At Bayer, he served as Executive Vice President and Head of the Oncology Strategic Business Unit, overseeing the global oncology franchise and serving on the Executive Committee for Bayer Pharmaceuticals. Before that, he was Senior Vice President and Head of Global Oncology at Bristol-Myers Squibb, leading the vision, strategy, and execution of the immuno-oncology franchise.

---

The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028, with the insulin pump segment expected to grow from $5.26 billion to $21.65 billion by 2032. As reported by Fortune Business Insights, this rapid growth is driven by increasing diabetes prevalence and technological advancements in insulin delivery devices. Modular Medical, Inc. (NASDAQ: MODD, $.8865, an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com. On March 20, Modular Medical announced the execution of definitive subscription agreements with institutional and accredited investors for a private placement, which is expected to result in gross proceeds of approximately $12 million, before deducting fees and offering expenses. The private placement consists of the sale of units comprised of two shares of common stock, together with one warrant to purchase one share of common stock. The units are being sold at a purchase price of $1.92 per unit and were priced at-the-market under the rules of the Nasdaq Stock Market. The private placement is expected to close on or about March 25, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the proceeds from the private placement for supply-chain optimization and margin improvement on its MODD1 product in preparation for broad commercial availability and preparing the submission to the FDA of a tubeless version of the MODD1 product, which the Company currently believes it will submit to the FDA in the third quarter of 2025, along with ongoing work to obtain the CE mark required for overseas markets. On Jan. 30, Modular Medical announced that BSI Group will serve as the notified body for the European regulatory clearance process. Unlike the U.S. process, European Union (“E.U.”) clearance of a medical device is driven by a series of audit steps driven by a third party, known as a notified body, retained by the sponsor of the device to determine safety and efficacy, and the notified body then certifies that the CE mark standards have been met. Once the CE mark is obtained, a device can be marketed and sold in Europe and other areas that rely on the CE mark. BSI Group will serve as the notified body for Modular Medical for its CE clearance process. “The MODD1 insulin pump is an ideal fit for the European marketplace,” stated Jeb Besser, CEO of Modular Medical. “With U.S. clearance in hand, we are focusing our regulatory efforts on the opportunity in the E.U. In Europe, pump penetration has been challenged with its high cost, considerable environmental impact and complexity of use. We believe that our combination of simplicity to learn and use and the low cost of our device, combined with its lower carbon footprint, reusable electronics and attractive form factor for the patient, will motivate more multiple daily injectors to adopt pumping.” After the close on December 19, Modular Medical announced a licensing and partnership agreement with Nudge BG. Lane Desborough, CEO of Nudge BG stated, “We are very excited to partner with Modular Medical to bring the next generation of automated insulin delivery (“AID”) to the marketplace. Nudge BG’s adaptive full closed loop AID technology, unlike the present Hybrid Closed Loop products, complements Modular Medical’s easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor. We believe most people living with insulin-requiring diabetes find it difficult or impossible to sustain the therapy effort which contemporary AID systems demand, including counting carbohydrates and calculating bolus delivery amounts, preventing them from reaping the benefits of the present technology. It has been the goal of Nudge BG to design an AID system that will truly make the diabetes management experience both effective and less burdensome for users. Our system will fully automate mealtime insulin delivery, freeing people with diabetes from the risk and difficulty of bolusing, while still achieving glycemic goals.”   Paul DiPerna, President and CTO of Modular Medical, stated “Our goal at Modular Medical is to bring the benefits of insulin pump technology to the approximately 80% of potential adopters who are not on pumps because they see current AID-enabled systems as too complex, too cumbersome, and too costly. The Nudge BG partnership is another step in our efforts to make the experience of diabetes management as low touch and simple as possible by reducing the amount of time, training, and effort a user will spend daily on managing insulin, while still providing the beneficial results of pumping as compared to multiple daily injections.” Mr. Desborough has been developing control algorithms in safety-critical industries for the past 35 years. He was formerly Co-Founder and Chief Engineer of Bigfoot Biomedical and previously served as Chief Engineer, Closed Loop/Insulin Delivery at Medtronic Diabetes. Mr. Desborough has been developing commercial AID systems since 2010, soon after his son was diagnosed with type-1 diabetes. On November 11, Modular Medical, Inc.’s Chief Executive Officer, Jeb Besser delivered a presentation titled “Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing.” He was also available for a 5-10 minute Q&A session at the end of the presentation.
On Nov. 7, Modular Medical announced successful results from its pre-clinical GLP-1 proof of concept study.  They highlighted the following: Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery, Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone, & Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility. “With these encouraging results, we are now planning to take this concept of a synergistic basal-bolus GLP-1 combination into a human trial using our MODD1 device. We are considering both existing fast acting GLP-1s and other peptides for this trial, as we see this as a platform technology that could be used for more personalized titration for both non-responder or non-adherent patients experiencing GI and other issues with long acting GLP-1s, as well as for other specialty applications in metabolic therapies. This type of application is well suited for our MODD1 pump, given its quick training time, simple interface, high accuracy at low flow rates, reusable low-cost electronics, and a prefill-capable 3mL reservoir,” stated Jeb Besser, CEO of Modular Medical. In October, Modular’s CEO was interviewed by Carole Sullivan on the Today In Nashville program affiliated with Channel 4 WSMV. The segment is called “New Tools for Treating Diabetes by Modular Medical.” You may watch the video now at this link. On September 18, Modular Medical announced the issuance of U.S. Divisional Patent Application No. 17/968,599. “The issuance of this patent and the associated claims represent a major step in our efforts to protect the intellectual property in the MODD1 pump platform,” stated Jeb Besser, CEO of Modular Medical. “Some of the key features of our novel, low-cost and accurate insulin delivery technology are now protected by this important issued U.S. patent, which we believe represents a significant new barrier to entry. Our eight families of patents around our pump are an important part of our strategic value and market positioning, and we look forward to announcing further issuances on our portfolio in the future.” On Wednesday, September 4, Modular announced it has received U. S. Food and Drug Administration (“FDA”) clearance to market and sell its MODD1 pump in the United States. With its commercial manufacturing infrastructure substantially established, the Company anticipates the MODD1 should be available for sale in early 2025.

James (Jeb) Besser, CEO of Modular Medical (NASDAQ: MODD)

“For too long, the benefits of superior glycemic control achieved by insulin pumps have, due to cost and complexity, been restricted to only the most sophisticated, motivated and well-insured users. The goal of Modular Medical has always been to change this by making diabetes technology accessible and affordable to underserved communities. We seek to make the experience of going ‘on a pump’ simpler and less intimidating and to widen the base beyond the current pump users,” said Jeb Besser, CEO of Modular Medical.

Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP) closed at $.48, +3.90% over the last 5-days. Indaptus is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. On March 25, Indaptus announced that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston. Dr. Waltzman’s panel, titled “Ensuring Effective and Efficient Trials Through Clinical Operations” will be Monday, April 7th from 4:05PM – 4:35PM ET. On March 20, Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial. Initial data indicate that Decoy20 at the 30 million cell dose was generally well-tolerated, with a favorable safety profile and promising early signs of clinical benefit, including some patients demonstrating stable disease. Additionally, Decoy20 triggered short-term increases in multiple key immune system biomarkers (cytokines and chemokines), which play a crucial role in activating the body’s natural defenses against cancer. On March 12, Indaptus’ CEO, Jeffrey Meckler,  presented at Tribe Public’s Webinar Presentation and Q&A Event titled “Keys To The Kingdom: Unlocking The Power Of Your Immune System.” You may watch it now at this link. Indaptus’ chief medical officer, Roger Waltzman, M.D., M.B.A. moderated a panel at the annual CMO360 Summit, being held April 7-8 in Boston. Dr. Waltzman’s panel was titled “Ensuring Effective and Efficient Trials Through Clinical Operations.” On March 18, Indaptus announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity. effrey Meckler, CEO of Indaptus, commented, “This marks a pivotal step forward for Indaptus and our Decoy platform. Preclinical research has consistently shown that Decoy20 works synergistically with a checkpoint inhibitor, and we now have the opportunity to test that in patients for the first time. While this initial phase will focus on safety and tolerability, we are laying the groundwork for what could be a game-changing approach to treating solid tumors. This combination trial is not just a milestone – it’s an opportunity to showcase our platform’s versatility and move one step closer to improving patient outcomes.” On March 4, Indaptus announced that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments. Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, commented, “The allowance of these patents in key international markets highlights the potential of our Decoy platform in the fight against chronic infectious diseases. With millions of people affected by HBV and HIV worldwide, expanding our intellectual property reinforces the novelty and therapeutic promise of our approach.” On Feb. 25, Indaptus Therapeutics announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California. Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity.”

In this presentation, Dr. Newman will discuss:

• The science behind Indaptus’ Decoy platform, a multi-immune receptor agonist designed to trigger broad innate and adaptive immune activation against tumors.

• How the Company’s “Pulse-Prime” approach supports safe and effective anti-tumor activity in pre-clinical models, including the role of Natural Killer (NK) cells.

• Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.

On Feb. 5, Indaptus announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene’s PD-1 checkpoint inhibitor, tislelizumab. Jeffrey Meckler, CEO of Indaptus, commented, “We are pleased to bring Canadian investigators and patients into our clinical efforts, creating a more diverse and robust data set. Health Canada’s approval followed a comprehensive review of our safety data and trial design. Expanding to Canada represents a significant step in our mission to evaluate Decoy20, a broad immune system activator, in patients with solid tumors.” Roger Waltzman, Chief Medical Officer, added, “The addition of Canadian trial sites should allow us to accelerate the collection of valuable clinical data more efficiently, and from a broader, more diverse population. This expansion is critical as we continue to evaluate Decoy20’s unique ability to activate both the innate and adaptive immune systems, potentially addressing the challenges associated with solid tumors. By enhancing our trial infrastructure, we aim to accelerate our understanding of Decoy20’s full therapeutic potential, refine its dosing regimen, and improve treatment outcomes for patients facing difficult-to-treat cancers. We are confident this progress will pave the way for key insights that could bring us closer to meaningful advances in cancer treatment.” On Jan 13, Indaptus announced that it has entered into securities purchase agreements with investors for the issuance and sale in a private placement priced at-the-market under Nasdaq rules of an aggregate of 2,109,383 of its shares of common stock and accompanying warrants to purchase up to an aggregate of 2,109,383 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.065. The closing of the offering is expected to take place on or about January 15, 2025, subject to the satisfaction of customary closing conditions. On Jan 8, Indaptus published its accomplishments in 2024 and outlines the Company’s strategic goals for the year ahead.

Advancing Decoy20 in Clinical Trials 2024 was a year of meaningful progress for Indaptus’ lead clinical candidate, Decoy20, a novel immunotherapy designed to harness both innate and adaptive immune responses. Highlights from the Company’s Phase 1 clinical trial include:

• Second Cohort Results (March 2024): Building on the Company’s November 2023 findings, Decoy20 demonstrated a broad immune response across multiple tumor types in patients, underscoring the platform’s potential as a monotherapy.

• Weekly-Dose Cohort Initiation (May 2024): After receiving Safety Review Committee approval, the Company dosed its first patient in the weekly-dose portion of the trial. Notably, no new, clinically significant treatment-related adverse effects were observed.

• Higher Dose Expansion (September 2024): Following a positive safety review, Indaptus initiated a higher-dose weekly regimen, further expanding the scope of the trial to evaluate Decoy20’s safety and efficacy.

Key Scientific Presentations, Publications and Advancements Indaptus showcased Decoy20’s potential through a variety of presentations at major industry conferences and peer reviewed journals:

• AACR Annual Meeting (April 2024): Demonstrated that Decoy activates multiple innate and adaptive immune cell types, highlighting its promise as an anti-tumor therapeutic.

• ASCO Annual Meeting (June 2024): Shared promising preliminary results, including immune marker activation in patients with advanced solid tumors following a single dose of Decoy20.

• STING & TLR Targeted Therapies Summit (June 2024): Dr. Michael Newman was named meeting Chairperson for the second year in a row, and presented pre-clinical and clinical Decoy data.

• Frontiers in Immunology (November 2024): Dr. Michael Newman’s groundbreaking research on the Decoy platform was published in Frontiers in Immunology, further validating the Company’s scientific foundation and enhancing visibility within the scientific community.

• Society for Immunotherapy of Cancer (SITC) (November 2024): Presented encouraging data highlighting consistent safety outcomes with weekly Decoy20 dosing, while demonstrating its sustained ability to activate the immune system over time.

• Decoy platform: The Company made significant progress expanding its Decoy platform, successfully producing engineered Decoy bacteria designed to activate targeted immune pathways, enhancing its potential for broader therapeutic applications.

Clinical Supply Agreement with BeiGene

In October 2024, Indaptus achieved a key milestone when it announced a clinical supply agreement with BeiGene to advance the evaluation of Decoy20 in combination with their PD-1 checkpoint inhibitor, tislelizumab. This agreement underscores the potential versatility of the Decoy platform as a standalone therapy and in synergy with an approved immunotherapy treatment modality. This clinical combination is important because, in pre-clinical animal models, Decoy20 demonstrated significant anti-tumor synergy in combination with a PD-1 checkpoint inhibitor.

Financial Strength Indaptus raised a total of $5.5 million in 2024 through a series of strategic financing initiatives, ensuring funding to support ongoing research and development efforts into 2025.

2025 Outlook

Jeffrey Meckler, CEO of Indaptus Therapeutics, commented, “As we enter 2025, we remain committed to advancing Decoy20 through clinical trials and exploring its combination potential with BeiGene’s tislelizumab. We are excited about the progress we made in 2024 and optimistic about the transformative potential of our platform to address some of the most challenging cancers.”

Indaptus intends to maintain its commitment to robust data generation, with plans to share new findings at leading scientific forums as they become available, while actively pursuing opportunities to expand the applications of its Decoy platform.

The Company currently anticipates that it will achieve the following milestones in the first half of 2025:

• Launch of Combination Cohort: The Company plans to open an amendment to its clinical trial to include a combination cohort evaluating Decoy20 in conjunction with the PD-1 checkpoint inhibitor, tislelizumab.

• Expansion of Clinical Sites: Building on its progress in 2024, the Company intends to increase the number of participating clinical sites beyond the eight active locations at the end of last year, enabling broader patient enrollment.

• Higher Dose Cohort Update: The Company plans to provide an update on the patients treated in the higher dose expansion cohort, providing insights into safety and immune activation at this dose level.

• First Patient Dosed in Combination Cohort: The Company aims to start dosing the first patients in the combination cohort, marking an important step in evaluating Decoy20’s synergistic potential with checkpoint inhibitors.

The company believes these milestones, if achieved, will represent significant advancements in the clinical development of Decoy20 and the broader Decoy platform.

Lantern (LTRN) closed at $3.21, +7.36% over the last 5-days.  Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs. Lantern announced (Mar. 27) financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug development enhancements, and other operational progress. Lantern highlighted the following:

• HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025.

• LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential.

• Successfully dosed multiple patient cohorts in Phase 1A clinical trials for both LP-184 and LP-284, advancing these synthetic lethal drug candidates toward drug concentration levels that may show therapeutic efficacy in several cancers of high unmet patient need and with multiple orphan and fast track FDA designations.

• Demonstrated LP-184 synergy with checkpoint inhibitors in TNBC through MD Anderson collaboration, demonstrating ability to transform immunologically “cold” tumors into “hot” tumors by reshaping the tumor microenvironment and modulating T-cell activity in preclinical models.

• Starlight Therapeutics unveiled recurrent GBM trial design for STAR-001 at SNO 2024, featuring innovative STAR-001+spironolactone combination regimen that leverages synthetic lethality; assembled world-class Scientific Advisory Board from Johns Hopkins, UCSF, and Memorial Sloan Kettering.

• Showcased industry-leading capabilities in CNS therapeutic development using AI with patent-pending BBB permeability prediction algorithm with unprecedented performance –five of the top eleven rankings on Therapeutic Data Commons leaderboard and processing capabilities of 100,000 molecules per hour at industry-leading accuracy rates.

• Unveiled innovative AI-powered ADC development module that identified 82 promising targets and 290 target-indication combinations and potentially reducing development timelines by 30-50% and preclinical costs by up to 60% compared to traditional ADC development.

• The RADR^® AI platform surpassed 100 billion oncology-specific data points in 2024, accelerating precision drug development initiatives including biomarker discovery and signature creation, identification of mechanisms of action and synergistic combination regimens, ADC optimization, and continuing to power collaborations with emerging oncology companies and centers.

• Approximately $24 million in cash, cash equivalent

Lantern announced (Feb. 19) the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability. The application received a favorable PCT search report indicating no significant prior art, substantially strengthening its path to approval. The technology has demonstrated to-date exceptional performance in predicting BBB permeability across a wide range of chemical compounds, processing up to 100,000 molecules per hour with industry-leading accuracy. Notably, Lantern’s AI algorithms for BBB permeability prediction currently hold five of the top eleven positions on the Therapeutic Data Commons Leaderboard1. Lantern believes that this breakthrough capability can accelerate the drug development process by rapidly identifying compounds likely to cross the blood-brain barrier, a critical factor in developing treatments for central nervous system disorders and brain cancers. These identified compounds can then be accelerated and further developed by researchers in cancer drug development and other fields saving time and cost in early-stage molecular characterization. On Feb. 3, Lantern’s CEO Panna Sharma co-hosted a Tribe Public CEO Presentation and Q&A Webinar Event Titled “AI IN ACTION: Learn How lantern Pharma’s Business Model Has Multiple Paths Towards Success.”You may watch the event video at at this link: https://youtu.be/3LA5Y4Bk-0s?si=pWnx18m8imR2bRNe.

Shares of ADT Inc. (ADT), a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada, closed at $7.82. On Feb, 27, ADT announced strong full year earnings growth; GAAP EPS up 40%, Adjusted EPS up 25%, GAAP operating cash flows up 14%, Adjusted Free Cash Flow including interest rate swaps up 42%, Record recurring monthly revenue and customer retention, Returned $423 million to shareholders and continued leverage reduction & that they are Maintaining momentum into 2025 with strong cash flow and new $500 million share repurchase plan. ADT will release its Q1/2025 results on Thursday, April 2025.

On Jan. 22, ADT announced the appointment of Thomas Gartland to the Company’s Board of Directors as an additional independent director. In conjunction with his appointment, Gartland will join the Board’s Audit Committee. Gartland is chairman and chief executive officer of Montway Auto Transport, a privately held auto transport company, and has held this position since 2023. Prior to Montway, Gartland served as executive chairman of Scan Global Logistics and as president, North America, for Avis Budget Group. Gartland serves on the boards of Xenia Hotels & Resorts, Inc. and ABM.

GeoVax Labs, Inc. (Nasdaq: GOVX, $1.02), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced (MAR. 27) its financial results and key operational accomplishments for the year ended December 31, 2024 & highlighted the following: GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed, Additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in first half of 2025, Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to begin in second half of 2025, & Planning underway for Phase 2 clinical trial of Gedeptin(R) as treatment for first recurrent head and neck cancer in combination with immune checkpoint inhibitor. “We are entering 2025 from a position of strength following a pivotal year for GeoVax,” stated David Dodd, GeoVax’s Chairman and CEO. “In June 2024, we received BARDA’s Project NextGen award of nearly $400 million to advance GEO-CM04S1 in a Phase 2b clinical trial. Throughout the remainder of 2024, we were able to secure a high quality CRO partner and lay the foundation for our 10,000-patient study, progressing to producing the vaccine material for use in the clinical trial.” “We continue to build on our growing body of clinical evidence in support of GEO-CM04S1. In April 2024, we presented data at the 24th Annual World Vaccine Congress, highlighting data demonstrating vaccine induced immunity protects against infections, serious disease symptoms and death. GeoVax also reported positive initial safety and immune response data from the Phase 2 clinical trial of GeoVax as a booster in healthy adults who had previously received the Pfizer or Moderna mRNA vaccine and observed statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants. We continue to strive toward a solution for the critically underserved immunocompromised patient population, where the current mRNA vaccines do not provide adequate protection,” Dodd continued. GeoVax’s Chairman & CEO, David Dodd presented at Tribe Public’s CEO Presentation and Q&A Webinar Event titled “MPOX 2025: Navigating the Global Public Health Emergency.” The presentation covered another of topics that included the following:

• Mpox remains a global public health crisis in 2025, with Clade 1b exhibiting higher transmissibility and severity than Clade 2.
• The Democratic Republic of the Congo (DRC) is the epicenter, with over 60,000 suspected cases and 1,300 deaths in 2024 alone.
• The virus has now spread to multiple countries, including the U.S., Canada, and Europe, raising concerns about global containment.
• The U.S. has confirmed four Clade 1b cases (California, Georgia, New Hampshire, and New York), prompting the need for urgent action.
• The current vaccine supply chain is inadequate, relying heavily on a single non-U.S. manufacturer.
• Delays in vaccine distribution, high costs, and limited production capacity have exacerbated the crisis, particularly in Africa, where vaccine stockpiles remain largely unused due to logistical and political challenges.
• GEO-MVA, the GeoVax Mpox vaccine candidate is advancing to clinical evaluation, anticipated for H2 ’25.

On March 12, GeoVax announced its initial steps toward establishing a strategic presence in Europe, with the UK as its initial footprint. This move aligns with the Company’s commitment to advancing its vaccine and immunotherapy pipeline through global collaborations. Efforts are underway to identify a UK location best suited to align with GeoVax’s development and corporate strategy. The Company already has several established connections in the UK and broader European region, including:

• Scientific Expertise: Professor Teresa Lambe, a principal investigator at the Oxford Vaccine Group, recently joined GeoVax’s Scientific Advisory Board. Professor Lambe played a pivotal role in the development of the Oxford/AstraZeneca COVID-19 vaccine and has extensive experience in vaccine design and evaluation.

• Manufacturing Partnerships: GeoVax maintains an existing contract development and manufacturing organization (CDMO) relationship with Oxford Biomedica PLC (Oxford, UK), as well as additional collaborations with Oxford Biomedica (France), with facilities in Strasbourg and Lyon.

• Technology Licensing: The Company has a broad licensing agreement with ProBioGen AG (Berlin, Germany) to utilize their AGE1 continuous avian cell line for the manufacture of MVA vaccines.

• European Collaborations: GeoVax currently collaborates with multiple European-based service providers and UK academic partners, reinforcing the strategic rationale for establishing a presence within the region.

To support this initiative, GeoVax is working closely with Professor Teresa Lambe and clinical investigators and scientists in Oxford and other academic centers across the UK to develop preclinical, translational, and clinical projects supporting its pipeline. Additionally, Dr. Deborah Spencer, a highly regarded expert in industry-academic partnerships and public health development, has recently been retained to facilitate and coordinate initiatives in the UK and Europe. Establishing a strategic presence in Europe will support GeoVax’s infectious disease vaccine development efforts and play a key role in advancing Gedeptin(R), the Company’s lead immuno-oncology candidate. Currently in clinical development for the treatment of advanced head and neck cancers, Gedeptin is anticipated to be further developed for use with immune checkpoint inhibitors as a potential treatment for various other solid tumors. GeoVax holds worldwide rights to Gedeptin for all indications.

IN8bio, Inc. (Nasdaq: INAB, $.1521) is a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies. IN8bio announced (March 31) a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. “T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis and low IL-6 secretion, representing a powerful modality with the potential to overcome the limitations of current CD-3 based engager therapies,” said William Ho, CEO, and co-founder of IN8bio. Our novel gamma-delta T cell engager platform, presented for the first time at AACR 2025, demonstrates how we can combine the innate tumor-recognition capabilities of gamma-delta T cells with the capacity for significant cell expansion and the specificity of bispecific engagers to drive a potent, targeted immune response against multiple target antigens. These early findings in AML and B-ALL support our broader strategy to harness the unique biology of these cells across a range of cancers.” On March 13, IN8bio reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. William Ho, Chief Executive Officer and co-founder of IN8bio, commented, “In 2024, IN8bio made significant progress advancing its pipeline of gamma-delta T cell therapies and positioning the Company for long-term success. The INB-100 program continues to demonstrate 100% long term durable response rates as of January 17, 2025, reinforcing its potential to help treat and maintain remissions in high-risk AML patients.” Mr. Ho continued, “We have also disclosed our novel INB-600 platform, which we believe has the potential to reshape the T cell engager landscape by potentially improving both the durability of response and safety compared to existing CD3 targeting TCE therapies. Throughout 2025, we remain focused on driving innovation, advancing our clinical programs and delivering value to patients and our stakeholders.” On March 12, Tribe Public hosted the Webinar Event “The DeltEx Platform: Advancing Innovative Immune Solutions for Cancer and Autoimmune Diseases” featuring IN8bio’s’ CEO William Ho. Watch it below now: On March 3, IN8Bio unveiled INB-600, its potentially breakthrough next generation γδ T cell-based TCE platform. It is designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This groundbreaking platform leverages γδ T cells’ unique properties targeting applications in both oncology and autoimmune indications with potentially greater safety and tolerability than current CAR-T and TCE approaches. The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 demonstrated: Rapid and sustained B-cell depletion – target cells were eradicated as γδ T cells continued expanding up to 450-fold with continued proliferation until the target cells were undetectable, Simultaneous expansion and activation of both major γδ T cell subsets (Vδ1+ and Vδ2+) leverages both the rapid antigen presenting properties of Vδ2+ T cells and the longer-term resistance against exhaustion and tissue residence properties of Vδ1+ T cells, potentially resulting in deeper B cell depletion, & Lower cytokine (IL-6) secretion, potentially reducing the risk of dangerous side effects such as CRS and ICANs, two of the most severe side effects limiting CAR-T and traditional CD3-TCE adoption in autoimmune indications. On Feb. 11, IN8bio announced encouraging new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100, an allogeneic gamma-delta T cell therapy designed to help patients with complex leukemias, including AML. INB-100, given following hematopoietic stem cell transplantation (HSCT), is demonstrating the potential to achieve durable long-term remissions and improved survival. The data will be presented at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, hosted in Honolulu, HI. Highlights from today’s release are as follows: 100% of AML patients remain relapse-free, Trial displays improved survival outcomes vs. standard treatment, Results demonstrate activity even with older, high-risk patients receiving reduced intensity conditioning (RIC). William Ho, Chief Executive Officer and co-founder of IN8bio, stated, “We’re incredibly pleased with our efforts to continue to deliver consistent, long-term remission results with INB-100. It’s rare to see 100% relapse-free survival in high-risk AML patients, especially over a prolonged period. For patients who may not have had a clear path forward in the past, INB-100 is providing hope, extending survival, and demonstrating the potential to change the standard-of-care. What makes this even more exciting is the safety profile we’ve observed. Gamma-delta T cells are showing that they can do the job of fighting residual cancer cells without causing significant side effects like CRS or neurotoxicity—issues that often plague other cell therapies. As we continue to enroll patients and expand the trial network, we are working diligently to lay the groundwork for the future regulatory pathway towards a potential registrational trial. The IN8bio team is working hard to de-risk the future path to approval and to bring this innovative therapy towards broader patient access. We are committed to providing further updates later this year as we build momentum toward this goal.” On December 10, 2024, IN8bio announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant (HSCT) with reduced intensity conditioning (RIC) at the 2024 American Society of Hematology (ASH) Annual Meeting, being hosted in San Diego, CA. Dr. Joseph P. McGuirk, Schutte-Speas Professor of Hematology-Oncology, Division Director, Hematologic Malignancies and Cellular Therapeutics Medical Director, Blood and Marrow Transplant, The University of Kansas Cancer Center stated, “This data demonstrates the potential of allogeneic INB-100 gamma-delta T cells to provide durable relapse-free remissions in high-risk or relapsed AML patients undergoing HSCT. Older, frailer patients who receive non-myeloablative, reduced intensity conditioning regimens typically have a significant risk of relapse. Historically, approximately 25% of AML patients undergoing HSCT would be expected to have a leukemic relapse within the first 100 days post-transplant, with up to nearly 50% of such patients experiencing relapse by one-year, which remains the primary cause of death. The longer AML patients remain in remission post-HSCT, the greater their probability of survival. These observed long-term durable remissions using allogeneic gamma-delta T cells are very encouraging and we look forward to announcing additional data next year.”

QUOTE OF WEEK

Investing & Inspiration

1. “All change is not growth, as all movement is not forward.” –  Ellen Glasgow
2. “If you’re going through hell, keep going.” – Winston Churchill
3. “A will finds a way.” – Orison Swett Marden
4. “You can never plan the future by the past.” – Edmund Burke
5. “If you live to be a hundred, I want to live to be a hundred minus one day so I never have to live without you.” – A. A. Milne
6. “I am still learning.” – Michelangelo
7. “Every failure is a step to success.” – William Whewell
8. “I attribute my success to this – I never gave or took any excuse.” – Florence Nightingale
9. “A man should always consider how much he has more than he wants.” – Joseph Addison
10. “Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel
11. “No one has a greater asset for his business than a man’s pride in his work.” – Hosea Ballou
12. “In three words I can sum up everything I’ve learned about life: it goes on.” –  Robert Frost
13. “The most worth-while thing is to try to put happiness into the lives of others.” – Robert Baden-Powell
14. “A good beginning makes a good end.” – Louis L’Amour
15. “Humanity is acquiring all the right technology for all the wrong reasons.” – R. Buckminster Fuller
16. “There is a certain enthusiasm in liberty, that makes human nature rise above itself, in acts of bravery and heroism.” – Alexander Hamilton
17. “You don’t take a photograph, you make it.” – Ansel Adams
18. “The less we deserve good fortune, the more we hope for it.” – Lucius Annaeus Seneca
19. “Art is the right hand of Nature. The latter has only given us being, the former has made us men.” – Friedrich Schiller
20. “To begin, begin.” –  William Wordsworth
21. “Nature does not hurry, yet everything is accomplished.” – Lao Tzu
22. “The end of labor is to gain leisure.” – Aristotle
23. “People are not disturbed by things, but by the view they take of them.” – Epictetus
24. “Have patience. All things are difficult before they become easy.” – Saadi
25. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
26. “The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton
27. “The only true wisdom is in knowing you know nothing.” – Socrates
28. “Courage is knowing what not to fear.”– Plato
29. “The home is the chief school of human virtues.” – William Ellery Channing
30. “Be brave. Take risks. Nothing can substitute experience.” – Paulo Coelho
31. “There are no shortcuts in evolution.” – Louis D. Brandeis
32. “A friend may well be reckoned the masterpiece of nature.” –  Ralph Waldo Emerson
33. “Nature uses as little as possible of anything.” – Johannes Kepler
34. “Every new beginning comes from some other beginning’s end.” – Seneca
35. “Nothing ever becomes real till it is experienced.” – John Keats
36. “Nobody who ever gave his best regretted it.” – George Halas
37. “Honest disagreement is often a good sign of progress.” – Mahatma Gandhi
38. “A leader is one who knows the way, goes the way, and shows the way.” – John C. Maxwell
39. “They always say time changes things, but you actually have to change them yourself.” – Andy Warhol
40. “The secret of happiness is something to do.” – John Burroughs
41. “The world of reality has its limits; the world of imagination is boundless.”
42. “You begin with the possibilities of the material.” – Robert Rauschenberg
43. “The only Zen you can find on the tops of mountains is the Zen you bring up there.” – Robert M. Pirsig
44. “Leadership is the capacity to translate vision into reality.” – Warren Bennis
45. “A man should always consider how much he has more than he wants.” – Joseph Addison
46. “Happiness is good health and a bad memory.” –  Ingrid Bergman
47. “We pass through this world but once.” – Stephen Jay Gould
48. “Christmas waves a magic wand over this world, and behold, everything is softer and more beautiful.” – Norman Vincent Peale
49. “Nothing can have value without being an object of utility.” – Karl Marx
50. “Always turn a negative situation into a positive situation.” – Michael Jordan
51. “Courage is found in unlikely places.” – J. R. R. Tolkien
52. “One that would have the fruit must climb the tree.” – Thomas Fuller
53. “Someone is sitting in the shade today because someone planted a tree a long time ago.” – Warren Buffett
54. “We relish news of our heroes, forgetting that we are extraordinary to somebody too.” – Helen Hayes
55. “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” – George Bernard Shaw
56. “Everything in the world may be endured except continual prosperity.”  – Johann Wolfgang von Goethe
57. “Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt
58. “Time is money.” – Benjamin Franklin
59. “Change before you have to.” – Jack Welch
60. “Our deeds determine us, as much as we determine our deeds.” – George Eliot
61. “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
62. “Care and diligence bring luck.” – Thomas Fuller
63. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
64. “A man who is a master of patience is master of everything else.” – George Savile
65. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
66. “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
67. “Act as if what you do makes a difference. It does.” – William James
68. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
69. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
70. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
71. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
72. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
73. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
74. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
75. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
76. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
77. “Action is the foundational key to all success.” – Pablo Picasso
78. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
79. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
80. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
81. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
82. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
83. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
84. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
85. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
86. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
87. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
88. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
89. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
90. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
91. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
92. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
93. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
94. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
95. “There is little that can withstand a man who can conquer himself.” – Louis XIV
96. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
97. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
98. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
99. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
100. “No man was ever wise by chance.” – Lucius Annaeus Seneca
101. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
102. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
103. “It does not matter how slowly you go as long as you do not stop.” – Confucius
104. “I want to put a ding in the universe.” – Steve Jobs
105. “Research is creating new knowledge.” – Neil Armstrong
106. “The reward for work well done is the opportunity to do more.” – Jonas Salk
107. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
108. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
109. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather
110. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
111. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy
112. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
113. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
114. “The best way out is always through.” – Robert Frost
115. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
116. “Without labor nothing prospers.” – Sophocles
117. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
118. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt
119. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller
120. “He who is brave is free.” – Lucius Annaeus Seneca
121. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk
122. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin
123. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll
124. “He who knows that enough is enough will always have enough.” – Lao Tzu
125. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
126. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama
127. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
128. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
129. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
130. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
131. “You must do the things you think you cannot do.”- Eleanor Roosevelt
132. “Success is dependent on effort.” – Sophocles
133. “Nobody who ever gave his best regretted it.” – George Halas
134. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
135. “And when I breathed, my breath was lightning.” – Black Elk
136. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
137. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
138. “If you want a guarantee, buy a toaster.” – Clint Eastwood
139. “We are an impossibility in an impossible universe.” – Ray Bradbury
140. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
141. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
142. “Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
143. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
144. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
145. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
146. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran
147. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
148. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
149. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
150. “There is more to life than increasing its speed.” – Mahatma Gandhi
151. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
152. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
153. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
154. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
155. “Life is too short for long-term grudges.” – Elon Musk
156. “There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
157. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
158. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
159. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
160. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
161. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
162. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
163. “Let there be work, bread, water and salt for all.” – Nelson Mandela
164. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
165. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
166. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
167. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
168. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
169. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
170. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
171. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
172. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
173. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
174. “Delete the negative; accentuate the positive!” – Donna Karan
175. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
176. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
177. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
178. “Everything has beauty, but not everyone sees it.” – Confucius
179. “A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
180. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
181. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
182. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
183. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
184. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
185. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
186. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
187. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
188. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
189. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
190. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
191. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
192. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
193. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
194. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
195. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
196. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
197. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
198. “There is little that can withstand a man who can conquer himself.” – Louis XIV
199. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
200. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
201. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
202. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese
203. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
204. “Never do anything against conscience even if the state demands it.”– Albert Einstein
205. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
206. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
207. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
208. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
209. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
210. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
211. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
212. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
213. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
214. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
215. “The secret of getting ahead is getting started.” – Mark Twain
216. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe